Hagit Eldar-Finkelman

Hagit Eldar-Finkelman's AcademicInfluence.com Rankings

Chemistry

#5693

World Rank

#6907

Historical Rank

chemistry Degrees

Hagit Eldar-Finkelman

Biology

#15599

World Rank

#19618

Historical Rank

Molecular Biology

#2705

World Rank

#2746

Historical Rank

Biochemistry

#2742

World Rank

#2930

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

Hagit Eldar-Finkelman's Degrees

PhD Biochemistry Tel Aviv University
Masters Biochemistry Tel Aviv University
Bachelors Chemistry Tel Aviv University

Why Is Hagit Eldar-Finkelman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Hagit Eldar-Finkelman is an Israeli scientist and a principal investigator of an active research laboratory at the Sackler School of Medicine at Tel Aviv University. Eldar-Finkelman’s research is focused on the signal transduction field and drug development targeting protein kinases. She is well known for her pioneering work on the functions of GSK-3 and its contribution to diabetes and other pathogenies, including depressive behavior, Alzheimer’s diseases, and Huntington’s diseases. Novel findings also include the unique evolution of GSK-3 isozymes. Eldar-Finkelman is a leading figure in developing novel substrate competitive inhibitors for GSK-3 with significant benefits as drug candidates.

(See a Problem?)

Hagit Eldar-Finkelman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
Glycogen synthase kinase 3: an emerging therapeutic target. (2002) (380)
Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. (1997) (325)
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS (2011) (291)
Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus (2004) (277)
Leptin Induces Insulin-like Signaling That Antagonizes cAMP Elevation by Glucagon in Hepatocytes* (2000) (249)
Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. (1999) (249)
Inactivation of Glycogen Synthase Kinase-3 by Epidermal Growth Factor Is Mediated by Mitogen-activated Protein Kinase/p90 Ribosomal Protein S6 Kinase Signaling Pathway in NIH/3T3 Cells (*) (1995) (219)
Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. (1994) (218)
Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. (2003) (174)
Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling* (2005) (165)
The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes (2002) (163)
Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse Model (2012) (155)
Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. (2002) (149)
Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3 (2003) (147)
Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. (1996) (135)
PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. (2005) (128)
Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle (2006) (111)
Role of glycogen synthase kinase-3β in early depressive behavior induced by mild traumatic brain injury (2007) (96)
Nuclear GSK-3β inhibits the canonical Wnt signalling pathway in a β-catenin phosphorylation-independent manner (2008) (81)
Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth (2014) (80)
Peptide inhibitors targeting protein kinases. (2009) (76)
Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3 (2013) (73)
Upregulation of glucose metabolism during intimal lesion formation is coupled to the inhibition of vascular smooth muscle cell apoptosis. Role of GSK3beta. (2001) (72)
Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. (2010) (69)
Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. (2008) (68)
Regulation of Ribosomal S6 Protein Kinase-p90rsk, Glycogen Synthase Kinase 3, and β-Catenin in Early Xenopus Development (1999) (64)
Substrate competitive GSK-3 inhibitors - strategy and implications. (2010) (63)
A unique type of GSK-3 inhibitor brings new opportunities to the clinic (2016) (60)
Lithium-mediated phosphorylation of glycogen synthase kinase-3β involves PI3 kinase-dependent activation of protein kinase C-α (2007) (58)
Peptides targeting protein kinases: strategies and implications. (2006) (50)
Identification of Novel Glycogen Synthase Kinase-3β Substrate-interacting Residues Suggests a Common Mechanism for Substrate Recognition* (2006) (48)
Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment (2003) (46)
Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. (2012) (46)
Selective loss of glycogen synthase kinase‐3α in birds reveals distinct roles for GSK‐3 isozymes in tau phosphorylation (2011) (45)
Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. (2004) (44)
Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β‐peptide (2011) (43)
GSK-3 inhibition: achieving moderate efficacy with high selectivity. (2013) (41)
Distinct molecular regulation of glycogen synthase kinase-3alpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. (2011) (40)
The SIL gene is essential for mitotic entry and survival of cancer cells. (2007) (40)
Structure-based optimization of oxadiazole-based GSK-3 inhibitors. (2013) (39)
GSK3β and β-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer (2010) (39)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. (2013) (33)
Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C betaII in the diabetic fat tissue. (2008) (32)
GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. (2010) (30)
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration (2021) (28)
Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. (2011) (22)
Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor. (2011) (22)
Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. (2017) (22)
New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta. (2008) (22)
Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3 (2010) (20)
Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward (2022) (18)
Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition (2017) (16)
GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. (2020) (14)
Distinct Molecular Regulation of Glycogen Synthase Kinase-3α Isozyme Controlled by Its N-terminal Region (2011) (12)
Exploiting substrate recognition for selective inhibition of protein kinases. (2012) (11)
GSK-3 and lysosomes meet in Alzheimer’s disease (2013) (11)
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site (2020) (10)
Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease (2021) (9)
Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3 (2017) (9)
Glycogen synthase kinase-3--a promising therapeutic target: Dr Hagit Eldar-Finkelman interviewed by Emma Quigley. (2006) (5)
GSK-3β Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds (2015) (5)
proteasome degradation of insulin receptor substrate-1 (2010) (4)
New Insights into the Autoinhibition Mechanism of Glycogen Synthase Kinase-3 β (2008) (2)
Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor (2016) (2)
An Exercise-Induced Metabolic Shield in Distant Organs Blocks Cancer Progression and Metastatic Dissemination (2022) (2)
GSK-3β Inhibition in Birds Affects Social Behavior and Increases Motor Activity (2022) (1)
Abstracts of the 15th Annual Meeting of the Israel Society for Neuroscience Eilat, Israel, December 3–5, 2006 (2006) (1)
Monitor and Molecules. (2001) (1)
Editorial [Hot Topic: GSK-3 in Health and Disease (Guest Editor: H. Eldar-Finkelman)] (2006) (1)
AUTHOR COPY ONLY Glycogen synthase kinase 3b mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1 (2010) (0)
Contents Vol. 85, 2015 (2015) (0)
Overexpression of Protein Kinase C α in Swiss/3T3 Cells Reduces The Number of Both High and Low Affinity of the Epidermal Growth Factor Receptors (1991) (0)
Glycogen Synthase Kinase 3β Inhibition and βcatenin Activation Contribute to Enhanced Survival After Radiation in Pancreatic Cancer Cells (2007) (0)
Implications Peptides Targeting Protein Kinases : Strategies and (2006) (0)
Prospects in GSK-3 Signaling: From Cellular Regulation to Disease Therapy (2022) (0)
2737 Effect of X-Irradiation on Dendritic Spines Morphology of Hippocampal Neurons (2007) (0)
Erratum: The SIL gene is essential for milotic entry and survival of cancer cells (Cancer Research (2007) 67, (4022-4027)) (2007) (0)
Autoimmune Encephalomyelitis by Glycogen Regulation of Th1 Cells and Experimental (2013) (0)
VIVO AND IN VITRO STUDIES IN in the Alzheimer Disease Mouse Model : Mammalian Target of Rapamycin Activity Restores Lysosomal Acidification and -Amyloid Pathology and β Ameliorates Inhibition of Glycogen Synthase Kinase-3 Molecular Bases of Disease: (2013) (0)
GSK 3 β and β-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer 1 (2010) (0)
Insulin Resistance and Glycogen Synthesis: Roles in Liver, Muscle and Adipose Tissue (2002) (0)

This paper list is powered by the following services:

Other Resources About Hagit Eldar-Finkelman

en.wikipedia.org

What Schools Are Affiliated With Hagit Eldar-Finkelman?

Hagit Eldar-Finkelman is affiliated with the following schools:

Hagit Eldar-Finkelman's Academic­Influence.com Rankings

Hagit Eldar-Finkelman's Degrees

Why Is Hagit Eldar-Finkelman Influential?

Hagit Eldar-Finkelman's Published Works

Published Works

Other Resources About Hagit Eldar-Finkelman

What Schools Are Affiliated With Hagit Eldar-Finkelman?

Hagit Eldar-Finkelman's AcademicInfluence.com Rankings